Late adverse effects of childhood acute lymphoblastic leukemia treatment on developing dentition

被引:8
|
作者
Immonen, Egle [1 ,2 ]
Nikkila, Atte [1 ,3 ,4 ]
Peltomaki, Timo [2 ,5 ,6 ]
Aine, Liisa [2 ,5 ]
Lohi, Olli [1 ,3 ,4 ]
机构
[1] Tampere Univ, Fac Med & Hlth Technol, Tampere Ctr Child Adolescent & Maternal Hlth Res, Tampere, Finland
[2] Tampere Univ Hosp, Dept Ear & Oral Dis, Tampere, Finland
[3] Tampere Univ, Tays Canc Ctr, Tampere, Finland
[4] Tampere Univ Hosp, Tampere, Finland
[5] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland
[6] Univ Eastern Finland, Inst Dent, Kuopio, Finland
关键词
defect; dentition; development; leukemia; survivor; STEM-CELL TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; DENTAL ANOMALIES; RISK-FACTORS; ORAL-HEALTH; CHILDREN; CANCER; CHEMOTHERAPY; SURVIVORS; ABNORMALITIES;
D O I
10.1002/pbc.29200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Childhood cancer survivors show a variety of late adverse effects on dental health. The purpose of this study was to examine the prevalence and severity of dental abnormalities in permanent dentition in childhood leukemia survivors. Materials and methods Retrospective analysis of panoramic radiographs was performed for 178 childhood leukemia survivors aged below 17 years at the time of diagnosis. Sex, age at diagnosis, interval between ALL diagnosis and the follow-up radiograph, treatment protocol, and risk grouping were recorded. Abnormalities of tooth development and defect index were used to assess the frequency and severity of dental abnormalities. Results One hundred eight (61%) patients had no dental abnormalities at follow-up examination at a median of 6.1 years after diagnosis. Microdontia was more frequent in children under 6 years of age at the time of diagnosis (5.7% vs. 0.6%, p < .001). Significant differences were noted between distinct ALL treatment protocols with more common microdontia in patients treated according to the NOPHO ALL2008 protocol. Tooth agenesis was more frequent in patients that underwent therapy according to high-risk arms compared to intermediate- or standard-risk arms (3.8% vs. 1.4%, p = .01). Patients under 6 years of age at diagnosis had a significantly higher average defect index score than older patients (7.0 vs. 2.8, p = .01). Conclusions Children and adolescents who received ALL treatment were at risk for dental damage. Young age and high-intensity therapy were associated with the severity of dental abnormalities.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Late effects in survivors of childhood acute lymphoblastic leukemia in the context of selected gene polymorphisms
    Kwiecinska, Kinga
    Strojny, Wojciech
    Pietrys, Danuta
    Bik-Multanowski, Miroslaw
    Siedlar, Maciej
    Balwierz, Walentyna
    Skoczen, Szymon
    ITALIAN JOURNAL OF PEDIATRICS, 2018, 44
  • [22] Late-effects of Chemoradiotherapy on Growth and Puberty in Survivors of Childhood Acute Lymphoblastic Leukemia
    Eltan, Sevgi Bilgic
    Akcay, Arzu
    Bayramoglu, Elvan
    Eltan, Mehmet
    Akcay, Teoman
    Salcioglu, Zafer
    Aydogan, Gonul
    TRENDS IN PEDIATRICS, 2022, 3 (04): : 163 - 169
  • [23] Late mortality after childhood acute lymphoblastic leukemia (ALL).
    Robison, LL
    Francisco, L
    Gaynon, P
    Sather, H
    Trigg, M
    Reaman, G
    Bleyer, WA
    Carroll, W
    Bhatia, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 801S - 801S
  • [24] LATE MARROW RECURRENCES IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    CHESSELLS, JM
    BREATNACH, F
    BRITISH MEDICAL JOURNAL, 1981, 283 (6294): : 749 - 751
  • [25] Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health
    Ness, Kirsten K.
    Armenian, Saro H.
    Kadan-Lottick, Nina
    Gurney, James G.
    EXPERT REVIEW OF HEMATOLOGY, 2011, 4 (02) : 185 - 197
  • [26] Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study
    Hiroki Hori
    Tooru Kudoh
    Shinichiro Nishimura
    Megumi Oda
    Makoto Yoshida
    Junichi Hara
    Akio Tawa
    Ikuya Usami
    Akihiko Tanizawa
    Keiko Yumura-Yagi
    Koji Kato
    Ryoji Kobayashi
    Yoshihiro Komada
    Keitaro Matsuo
    Keizo Horibe
    International Journal of Clinical Oncology, 2017, 22 : 387 - 396
  • [27] Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study
    Hori, Hiroki
    Kudoh, Tooru
    Nishimura, Shinichiro
    Oda, Megumi
    Yoshida, Makoto
    Hara, Junichi
    Tawa, Akio
    Usami, Ikuya
    Tanizawa, Akihiko
    Yumura-Yagi, Keiko
    Kato, Koji
    Kobayashi, Ryoji
    Komada, Yoshihiro
    Matsuo, Keitaro
    Horibe, Keizo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (02) : 387 - 396
  • [28] RELAPSE IN ACUTE LYMPHOBLASTIC LEUKEMIA OF CHILDHOOD - TREATMENT AND RESULTS
    LUDWIG, R
    BRANDEIS, WE
    GEIGER, H
    KLINISCHE PADIATRIE, 1979, 191 (06): : 540 - 545
  • [29] Costs estimates in the treatment of childhood acute lymphoblastic leukemia
    Miklos, I.
    Miron, C. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 462 - 462
  • [30] On target for advances in the treatment of childhood acute lymphoblastic leukemia
    Carroll, WL
    BLOOD, 2005, 105 (02) : 438 - 439